Checking Blood Sugar Tracking in Patients With Heart Pumps
Compares a glucose sensor with the A1c test in people with diabetes and heart pumps.
Key facts
- Who runs it
- Mayo Clinic
- Where
- Rochester, United StatesSee the site
- Trial code
- Registry title
- A Study of Glycemic Control in Left Ventricular Assist
- Status
- Recruiting
- People taking part
- 20 people, planned
- Started
- 10 Nov 2023
- Expected to end
- Jul 2027
- Type of study
- Observational
- Treatments tested
- Freestyle Libre 3 Continuous Glucose Monitor (CGM)
- Record updated
- 8 May 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with type 2 diabetes who have had a left ventricular assist device (LVAD) heart pump for more than 3 months.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Type 2 diabetes, with an LVAD (HeartWare or HeartMate 3) implanted after 2010 and more than 3 months ago
- Earlier treatment
- A centrifugal flow LVAD implanted at any time after 2010, more than 3 months ago. Any diabetes medicine regimen is allowed. A CGM already in place is allowed.
Main reasons for not taking part
- Type 1 diabetes
- Cannot return for the 3 month visit
- Cannot use a smartphone with the LibreLink app to upload sugar data
- Unwilling to take part
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Prior implantation of contemporary, centrifugal flow LVAD (HeartWare or HeartMate 3) at any time after 2010
- Diagnosis of type II diabetes mellitus
- Any antihyperglycemic regimen
- Greater than 3 months out from LVAD implantation
- Capable of utilizing smartphone device for LibreLink app for uploading glycemic data
- Patients may be enrolled who have preexisting CGM in place
Who cannot take part
- Type I diabetics
- Unable to return at 3 month evaluation
- Unwillingness to participate
Where in United States
- Mayo Clinic in RochesterRochester, United StatesContact: Sarah Schettle, PA-CTaking people
About the trial
What the trial wants to find out
The study is being conducted to understand if the hemoglobin A1c, a measurement of control of blood sugars over a 3-month time, is valid in patients with Left Ventricular Assist Devices (LVADs) in place. To understand whether it is an adequate measurement, the investigators will compare the A1c to results from a continuous glucose monitor (CGM) measurement of blood sugars. By monitoring blood sugars continuously, the investigators will also assess whether they can get better control of blood sugars with a CGM, including avoiding low blood sugars.
The group in the trial
- Left Ventricular Assist Device (LVAD) supported Type 2 Diabetes Mellitus (T2DM) Subjects
Subjects diagnosed with T2DM who have a LVAD will be provided a Freestyle Libre 3 CGM.
Treatment: Freestyle Libre 3 Continuous Glucose Monitor (CGM)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- GLYcemic Control Evaluation by Continuous Glucose Monitor Compared With a1C in Left Ventricular Assist Device-supported Patients (GLYCEM1C-LVAD)
- Plain-language title
- Checking Blood Sugar Tracking in Patients With Heart PumpsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 8 May 2026